OMEROS CORP Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature
OMEROS CORP (OMER) reported Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature of -$12.93 million for the 12-month period ending 2018-12-31, per its 10-K filed 2020-03-02.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature · last filed 2020-03-02
- OMEROS CORP adjustments to additional paid in capital, convertible debt with conversion feature for fiscal 2018 was -$12.93M.
| Period end | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 12 month | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 12 month as first filed |
|---|---|---|
| 2018-12-31 | -$12.93M 10-K · filed 2020-03-02 | $12.93M 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |